A study of ASP2151 in subjects with recurrent outbreaks of genital herpes.

Official Title

A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes.

Conditions

  • Herpes Genitalis

Study Type

Interventional

Study Design

Treatment, Randomised, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study.

Further Details

Primary Outcome Measures:

  • To compare the efficacy and safety of ASP2151 with valacyclovir and placebo in the acute treatment of recurrent genital Herpes Simplex Virus Infection

Secondary Outcome Measures:

  • Pharmacokinetics in study patients

For more infomation visit Clinicaltrials.gov

Study Start

June 2007

Eligibility & Criteria

  • Ages Eligible for Study: 18 Years and older
  • Genders Eligible for Study: Both
  • Accepts Healthy Volunteers: No

Inclusion Criteria:

  • History of genital HSV documented by laboratory testing at screening
  • 4 or more episodes of genital herpes during the past 12 months  

Exclusion Criteria:

  • Subject is immunocompromised

Total Enrolment

Estimated to be 650

Contact Details

Please refer to this study by its ClinicalTrials.gov identifier: NCT00486200 

Contact:

Astellas Pharma US Medical Information  
Phone number: 800-727-7003
Email: clintrials.info@us.astellas.com

All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.